Tamalunas A, et al. Benign Prostate Hyperplasia - Current Medical Therapy, New Developments, and Side Effects. Ther Umsch. 2023;80(3):113–22.

Article  PubMed  Google Scholar 

Kim EH, et al. Management of Benign Prostatic Hyperplasia. Annu Rev Med. 2016;67:137–51.

Article  CAS  PubMed  Google Scholar 

Koudonas A, et al. Overview of current pharmacotherapeutic options in benign prostatic hyperplasia. Expert Opin Pharmacother. 2023;21:1–14.

Google Scholar 

Lokeshwar SD, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 2019;8(5):529–39.

Article  PubMed  PubMed Central  Google Scholar 

Speakman M, et al. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 2015;115(4):508–19.

Article  PubMed  Google Scholar 

Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22(Suppl 1):1–6.

PubMed  Google Scholar 

Lee SWH, et al. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci Rep. 2017;7(1):7984.

Article  PubMed  PubMed Central  Google Scholar 

Lerner LB, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I, Initial Work-up and Medical Management. J Urol. 2021;13:101097JU0000000000002183.

Yu ZJ, et al. Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. Front Pharmacol. 2020;11:658.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tempany CM, et al. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate. 1993;22(1):39–42.

Article  CAS  PubMed  Google Scholar 

McConnell JD, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.

Article  CAS  PubMed  Google Scholar 

McConnell JD, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. New England J Med. 1998;26;338(9):557–63.

Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020;113(1):21–50.

Article  CAS  PubMed  Google Scholar 

Fang Q, et al. Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia. Clin Breast Cancer. 2019;19(5):e624–36.

Article  CAS  PubMed  Google Scholar 

Pompili M, et al. Risk of Depression Associated With Finasteride Treatment. J Clin Psychopharmacol. 2021;41(3):304–09.

Pinsky PF, et al. Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. Cancer. 2013;119(3):593–601.

Article  PubMed  Google Scholar 

Strand DW, et al. Targeting phenotypic heterogeneity in benign prostatic hyperplasia. Diff; Res Biol Divers. 2017;96:49–61.

Vickman RE, et al. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian J Urol. 2020;7(3):191–202.

Article  PubMed  Google Scholar 

Bechis SK, et al. Personalized medicine for the management of benign prostatic hyperplasia. J Urol. 2014;192(1):16–23.

Article  PubMed  PubMed Central  Google Scholar 

Wang K, et al. Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications. Asian J Androl. 2014;16(2):274–9.

Imperato-McGinley J, et al. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186(4170):1213–5.

Article  CAS  PubMed  Google Scholar 

Shabir I, et al. Phenotype, genotype and gender identity in a large cohort of patients from India with 5alpha-reductase 2 deficiency. Andrology. 2015;3(6):1132–9.

Article  CAS  PubMed  Google Scholar 

Drobnis EZ, Nangia AK. 5alpha-Reductase Inhibitors (5ARIs) and Male Reproduction. Adv Exp Med Biol. 2017;1034:59–61.

Article  PubMed  Google Scholar 

Niu Y, et al. Reduced levels of 5-alpha reductase 2 in adult prostate tissue and implications for BPH therapy. Prostate. 2011;71(12):1317–24.

Article  CAS  PubMed  Google Scholar 

Bechis SK, et al. Age and Obesity Promote Methylation and Suppression of 5alpha-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia. J Urol. 2015;194(4):1031–7.

Article  PubMed  PubMed Central  Google Scholar 

Kang PM, et al. Correlation between 5-alpha reductase type 2 protein expression and methylation of 5-alpha reductase type 2 promotor gene of benign prostatic hyperplasia. World J Urol. 2019;37(4):709–18.

Article  CAS  PubMed  Google Scholar 

Wang K, et al. Anti-proliferative activities of finasteride in benign prostate epithelial cells require stromal fibroblasts and c-Jun gene. PLoS ONE. 2017;12(2): e0172233.

Article  PubMed  PubMed Central  Google Scholar 

Lin ZM, et al. Methylated CpG dinucleotides in the 5-alpha reductase 2 gene may explain finasteride resistance in benign prostatic enlargement patients. Asian J Androl. 2021;23(3):266–272.

Ge R, et al. DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate. Am J Pathol. 2015;185(3):870–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moore LD, et al. DNA methylation and its basic function. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2013;38(1):23–38.

Article  CAS  PubMed  Google Scholar 

Sugiura M, et al. Epigenetic modifications in prostate cancer. International journal of urology : official journal of the Japanese Urological Association. 2021;28(2):140–9.

Article  CAS  PubMed  Google Scholar 

• Liu Z, et al. Upregulation of mir-1199–5p is associated with reduced type 2 5-alpha reductase expression in benign prostatic hyperplasia. BMC Urol. 2022;22(1):172. Expression of SRD5A2 in prostate tissue is linked to resistance against 5-ARIs. This paper elucidates the molecular mechanism by which miR-1199–5p regulates SRD5A2 protein expression at the post-transcriptional level, distinguishing it from the SRD5A2 methylation regulatory mechanism.

Sgrignani J, et al. Enzymatic and Inhibition Mechanism of Human Aromatase (CYP19A1) Enzyme. A Computational Perspective from QM/MM and Classical Molecular Dynamics Simulations. Mini Rev Med Chem. 2016;16(14):1112–24.

Wang Z, et al. Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5alpha-reductase 2. J Pathol. 2017;243(4):457–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xue B, et al. Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland. Prostate Cancer Prostatic Dis. 2020;23(3):465–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cooke PS, et al. Estrogens in Male Physiology. Physiol Rev. 2017;97(3):995–1043.

Article  PubMed  PubMed Central  Google Scholar 

Huang JJ, et al. Pharmaceutical evaluation of naftopidil enantiomers: Rat functional assays in vitro and estrogen/androgen induced rat benign prostatic hyperplasia model in vivo. Eur J Pharmacol. 2016;15(791):473–81.

Article  Google Scholar 

Dias JP, et al. Effects of Transdermal Testosterone Gel or an Aromatase Inhibitor on Prostate Volume in Older Men. J Clin Endocrinol Metab. 2016;101(4):1865–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer. 2011;18(5):R183–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armstrong AJ, et al. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. J Clin Oncol: Offic J Am Soc Clin Oncol. 2019;37(13):1120–9.

Article  CAS  PubMed  Google Scholar 

Konig P, et al. Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer Patients. Cancers. 2020 Sep 16;12(9).

Li H, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol. 2021;79(6):879–86.

Article  CAS  PubMed  Google Scholar 

Moon SJ, et al. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer. Theranostics. 2021;11(2):958–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hillebrand AC, et al. Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer. PLoS ONE. 2018;13(7): e0200613.

Article  PubMed  PubMed Central  Google Scholar 

Austin DC, et al. NF-kappaB and androgen receptor variant expression correlate with human BPH progression. Prostate. 2016;76(5):491–511.

Article  CAS  PubMed  Google Scholar 

Austin DC, et al. NF-kappaB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARIs resistance. Prostate. 2016;76(11):1004–18.

Article